These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10188306)

  • 1. [Benefits and limitations of mass screening. The natural history of breast cancer].
    Tubiana M
    Bull Acad Natl Med; 1998; 182(8):1593-610; discussion 1610-1. PubMed ID: 10188306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Organized breast cancer screening].
    Rouëssé J; Sancho-Garnier H;
    Bull Acad Natl Med; 2014 Feb; 198(2):369-86. PubMed ID: 26263710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [French screening program of breast cancer. Results from 5 districts (1989-1994)].
    Séradour B; Allemand H; Schaffer P
    Bull Cancer; 1997 Aug; 84(8):822-8. PubMed ID: 9339188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minority report - false negative breast assessment in women recalled for suspicious screening mammography: imaging and pathological features, and associated delay in diagnosis.
    Ciatto S; Houssami N; Ambrogetti D; Bonardi R; Collini G; Del Turco MR
    Breast Cancer Res Treat; 2007 Sep; 105(1):37-43. PubMed ID: 17115112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The costs and benefits of breast cancer screening.
    Miller AB
    Am J Prev Med; 1993; 9(3):175-80. PubMed ID: 8347369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A decentralized breast cancer screening program in the French department of Bas-Rhin].
    Schaffer P; Gairard B; Guldenfels C; Haehnel P; Dale G; Bellocq JP; Renaud R
    J Radiol; 2000 Aug; 81(8):845-57. PubMed ID: 10916002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MR Imaging as an Additional Screening Modality for the Detection of Breast Cancer in Women Aged 50-75 Years with Extremely Dense Breasts: The DENSE Trial Study Design.
    Emaus MJ; Bakker MF; Peeters PH; Loo CE; Mann RM; de Jong MD; Bisschops RH; Veltman J; Duvivier KM; Lobbes MB; Pijnappel RM; Karssemeijer N; de Koning HJ; van den Bosch MA; Monninkhof EM; Mali WP; Veldhuis WB; van Gils CH
    Radiology; 2015 Nov; 277(2):527-37. PubMed ID: 26110667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammography in symptomatic and asymptomatic patients.
    Stomper PC; Gelman RS
    Hematol Oncol Clin North Am; 1989 Dec; 3(4):611-40. PubMed ID: 2691492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Participation behaviour following a false positive test in the Copenhagen mammography screening programme.
    Andersen SB; Vejborg I; von Euler-Chelpin M
    Acta Oncol; 2008; 47(4):550-5. PubMed ID: 18465321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for breast cancer in 2018-what should we be doing today?
    Seely JM; Alhassan T
    Curr Oncol; 2018 Jun; 25(Suppl 1):S115-S124. PubMed ID: 29910654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of mass screening for breast cancer in the Somme district (France) between 1990 and 1996].
    Ganry O; Peng J; Dubreuil A
    Rev Epidemiol Sante Publique; 1999 Sep; 47(4):335-41. PubMed ID: 10519174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammography screening for breast cancer in Copenhagen April 1991-March 1997. Mammography Screening Evaluation Group.
    Lynge E
    APMIS Suppl; 1998; 83():1-44. PubMed ID: 9850674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of diagnostic work-up with subsequent attendance in a breast cancer screening program for false-positive cases.
    Seigneurin A; Exbrayat C; Labarère J; Delafosse P; Poncet F; Colonna M
    Breast Cancer Res Treat; 2011 May; 127(1):221-8. PubMed ID: 20809364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Women's anxieties caused by false positives in mammography screening: a contingent valuation survey.
    Yasunaga H; Ide H; Imamura T; Ohe K
    Breast Cancer Res Treat; 2007 Jan; 101(1):59-64. PubMed ID: 16821083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of 99mTc-MIBI scintimammography to the diagnosis of non-palpable breast lesions in relation to mammographic probability of malignancy.
    Carril JM; Gómez-Barquín R; Quirce R; Tabuenca O; Uriarte I; Montero A
    Anticancer Res; 1997; 17(3B):1677-81. PubMed ID: 9179217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How do I screen patients for breast cancer?
    Krontiras H; Bramlett R; Umphrey H
    Curr Treat Options Oncol; 2013 Mar; 14(1):88-96. PubMed ID: 23315271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-year risk of false positive screening mammograms and clinical breast examinations.
    Elmore JG; Barton MB; Moceri VM; Polk S; Arena PJ; Fletcher SW
    N Engl J Med; 1998 Apr; 338(16):1089-96. PubMed ID: 9545356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The detection and diagnosis of early, occult and minimal breast cancer.
    Hickey RC; Gallager HS; Dodd GD; Samuels BI; Paulus DD; Moore DL
    Adv Surg; 1976; 10():287-312. PubMed ID: 185891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Breast cancer: generalised screening in France from now on].
    Séradour B
    Rev Prat; 2004 Apr; 54(8):830-6. PubMed ID: 15274453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased risk of breast cancer in women with false-positive test: the role of misclassification.
    von Euler-Chelpin M; Kuchiki M; Vejborg I
    Cancer Epidemiol; 2014 Oct; 38(5):619-22. PubMed ID: 25035157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.